In 2023, the Oregon Legislature expanded the board’s mission through
Senate Bill 192 to “develop a plan for establishing upper payment limits on drugs sold in this state that are subject to affordability reviews under
ORS 646A.694.” An upper payment limit, or UPL, limits what purchasers in Oregon will pay for specific drugs. The Legislature said the UPL plan should include outreach to constituent groups.
To fulfill its mandate, the board worked with consultants Lou Savage and Myers and Stauffer LC to host 23 community meetings and focus groups in April, May and June 2024. The board chair, vice chair, and consultants met with representatives from hospitals, pharmacies, insurance companies, manufacturers, pharmacy benefit managers, advocacy groups, patients and consumers. The board also hosted question and answer sessions with constituents during the July 24 board meeting.
This page includes links to reports, slideshows, documents submitted by constituents, and video recordings.